Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses

Donald P Tashkin, Bradley E Chipps, Frank Trudo, James G Zangrilli, Donald P Tashkin, Bradley E Chipps, Frank Trudo, James G Zangrilli

Abstract

Background: The role of fixed airflow obstruction (FAO) in asthma is unclear.

Objective: To assess the relationship between FAO and clinical features of asthma and the effect of FAO on treatment response.

Methods: Post hoc descriptive analysis of data stratified by FAO category (screening post-albuterol FEV1/FVC <lower limit of normal [LLN] [FAO+] or ≥LLN [FAO-]) from two 12-week, randomized, placebo-controlled studies of budesonide/formoterol or the monocomponents in mild-moderate (study I; aged ≥6 years; NCT00651651; placebo run-in) or moderate-severe (study II; ≥12 years; NCT00652002; budesonide run-in) asthma patients.

Results: At baseline, FAO+ versus FAO- patients were more likely male and had longer asthma duration and worse pulmonary function. During the treatment period, lung function and asthma control measures with placebo were generally worse in FAO+ versus FAO- patients. Budesonide was effective on most end points in both FAO+ and FAO- patients. In contrast to FAO- patients, FAO+ patients were unresponsive to formoterol monotherapy in both study populations. Consistently greater improvements in most end points (including worsening of asthma as predefined by specific lung function parameters or clinical symptoms) were observed moving from formoterol to budesonide to budesonide/formoterol in both FAO+ and FAO- patients, with generally greater than additive effects on lung function with budesonide/formoterol in FAO+ patients.

Conclusions: FAO+ patients tended to be more impaired and at greater risk for an asthma event versus FAO- patients. While FAO+ patients were non-responsive to formoterol monotherapy, they retained responsiveness to budesonide and had the greatest lung function and control responses to budesonide/formoterol that were similar to or greater than responses of FAO- patients.

Keywords: Airflow limitation; airway inflammation; budesonide; combination therapy; formoterol; inhaled corticosteroid; lung function.

Figures

Figure 1.
Figure 1.
Adjusted* mean changes from baseline in % of withdrawals due to predefined asthma events± by FAO category (LLN definition) in study I (mild-to-moderate asthma) and study II (moderate-to-severe asthma). Run-in treatment was placebo for study I and lower dose budesonide for study II (see “Methods” section for run-in and treatment details). *Data presented as least-squares mean unless otherwise noted. ±Predefined criteria for an asthma event included: (1) decrease in am predose FEV1 ≥20% from randomization or a decrease to <45% (study I) or <40% (study II) of predicted normal, (2) ≥12 actuations of albuterol/day on ≥3 days within a 7-day period, (3) decrease in am PEF ≥20% from baseline on ≥3 days within a 7-day period, (4) ≥2 nights with an awakening due to asthma requiring rescue medication within any 7-day period and (5) clinical exacerbation requiring emergency treatment, hospitalization or use of an asthma medication not allowed by the protocol. BUD/FM, budesonide/formoterol; FAO, fixed airflow obstruction; LLN, lower limit of normal; PBO, placebo.
Figure 2.
Figure 2.
Adjusted* mean changes from baseline in % of asthma control days by FAO category (LLN definition) in study I (mild-to-moderate asthma) and study II (moderate-to-severe asthma). Run-in treatment was placebo for study I and lower dose budesonide for study II (see “Methods” section for run-in and treatment details). *Data presented as least-squares mean unless otherwise noted. BUD/FM, budesonide/formoterol; FAO, fixed airflow obstruction; LLN, lower limit of normal; PBO, placebo.
Figure 3.
Figure 3.
Adjusted* mean changes from baseline in predose FEV1 by FAO category (LLN definition) in study I (mild-to-moderate asthma) and study II (moderate-to-severe asthma). Run-in treatment was placebo for study I and lower dose budesonide for study II (see “Methods” section for run-in and treatment details). *Data presented as least-squares mean unless otherwise noted. BUD/FM, budesonide/formoterol; FAO, fixed airflow obstruction; FEV1, forced expiratory volume in 1 s; LLN, lower limit of normal; PBO, placebo.

References

    1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2012 update. Available from: [last accessed 19 Nov 2013]
    1. Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest. 2007;132:1882–1889.
    1. Guerra S, Martinez FD. Epidemiology of the origins of airflow limitation in asthma. Proc Am Thorac Soc. 2009;6:707–711.
    1. Grainge CL, Lau LC, Ward JA, Dulay V, Lahiff G, Wilson S, Holgate S, et al. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med. 2011;364:2006–2015.
    1. Jarjour NN, Erzurum SC, Bleecker ER, Calhoun WJ, Castro M, Comhair SA, Chung KF, et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med. 2012;185:356–362.
    1. Bergeron C, Al-Ramil W, Hamid Q. Remodeling in asthma. Proc Am Thorac Soc. 2009;6:301–305.
    1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2013 update. Available at: [last accessed 19 Nov 2013]
    1. Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, Jensen RL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008;63:1046–1051.
    1. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med. 1999;159:179–187.
    1. Stanojevic S, Wade A, Stocks J. Reference values for lung function: past, present, and future. Eur Respir J. 2010;36:12–19.
    1. Cerveri I, Corsico AG, Accordini S, Niniano R, Ansaldo E, Antó JM, Künzli N, et al. Underestimation of airflow obstruction among young adults using FEV1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax. 2008;63:1040–1045.
    1. Corren J, Korenblat PE, Miller CJ, O’Brien CD, Mezzanotte WS. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin Ther. 2007;29:823–843.
    1. Noonan M, Rosenwasser LJ, Martin P, O’Brien CD, O’Dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomized clinical trial. Drugs. 2006;66:2235–2254.
    1. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152:1107–1136.
    1. Teeter JG, Bleeker EG. Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest. 1998;113:272–277.
    1. Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, Silkoff PE. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69:549–565.
    1. Persdotter S, Lindahl M, Malm-Erjeflt M, von Wachenfeldt K, Korn SH, Stevens T, Miller-Larsson A. Cooperative inhibitory effects of budesonide and formoterol on eosinophil superoxide production stimulated by bronchial epithelial cell conditioned medium. Int Arch Allergy Immunol. 2007;143:201–210.
    1. Spoelstra FM, Postma DS, Hovenga H, Noordhoek JA, Kauffman HF. Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts. Thorax. 2002;57:237–241.
    1. Cooper PR, Kurten RC, Zhang J, Nicholls DJ, Dainty IA, Panettieri RA. Formoterol and salmeterol induce a similar degree of β2-adrenoceptor tolerance in human small airways but via different mechanisms. Br J Pharmacol. 2011;163:521–532.
    1. Horvath G, Mendes ES, Schmid N, Schmid A, Conner GE, Fregien NL, Salathe M, Wanner A. Rapid nongenomic actions of inhaled corticosteroids on long-acting β2-agonist transport in the airway. Pulmon Pharmacol Ther. 2011;24:654–659.
    1. Skevaki CL, Christodoulou I, Spyridaki IS, Tiniakou I, Georgiou V, Xepapadaki P, Kafetzis DA, Papadopoulos NG. Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus. Clin Exp Allergy. 2009;39:1700–1710.
    1. National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma – Full Report 2007. NIH Publication Number 08-4051, 2007.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren